Microdosing mushrooms means taking a very small amount of psilocybin-containing mushrooms, typically one-tenth to one-twentieth of a full psychoactive dose, on a repeating schedule. The goal is to stay below the threshold of any noticeable “trip” while potentially gaining subtle benefits to mood, creativity, or focus. The practice has exploded in popularity over the past decade, but the scientific evidence behind it is far more complicated than the enthusiastic testimonials suggest.
How Much Counts as a Microdose
A typical microdose falls in the range of 0.05 to 0.3 grams of dried psilocybin mushrooms, most commonly around 0.1 to 0.2 grams. For context, a moderate recreational dose is roughly 2 to 3.5 grams. The idea is that the amount should be “sub-perceptual,” meaning you shouldn’t feel high, see visual distortions, or experience any obvious altered state. In practice, though, a double-blind study published in Translational Psychiatry found that many participants could correctly tell whether they had taken an active microdose or a placebo, which suggests these doses aren’t always as imperceptible as the term implies.
One major challenge is consistency. Psilocybin concentration varies significantly between mushroom species, between individual mushrooms of the same species, and even between the cap and stem of a single mushroom. People who microdose typically grind dried mushrooms into a fine powder and mix the batch thoroughly before portioning it into capsules. This helps even out the concentration somewhat, but without laboratory testing, there’s no way to know the exact amount of psilocybin in any given dose.
Common Dosing Schedules
Most people who microdose follow a cycling schedule rather than taking a dose every day. The most widely used protocol, proposed by psychedelic researcher James Fadiman, involves one dosing day followed by two days off, then repeating. So you might dose on Monday, skip Tuesday and Wednesday, dose again Thursday, and so on. The off days are meant to prevent tolerance buildup and allow time to observe any lingering effects.
Another popular approach, associated with mycologist Paul Stamets, follows a pattern of four days on and three days off, sometimes combined with other supplements like lion’s mane mushroom and niacin. Neither schedule has been validated in rigorous clinical trials. Most people who microdose experiment to find what feels right for them, and many cycle on and off over periods of weeks or months.
What Happens in the Brain
Psilocybin is converted in the body into psilocin, which activates serotonin receptors in the brain. The receptor most closely linked to psychedelic effects is called 5-HT2A, which is found throughout the prefrontal cortex, the area involved in mood regulation, decision-making, and flexible thinking. At full doses, activating these receptors triggers the dramatic perceptual shifts people associate with a psychedelic experience. At microdose levels, the activation is far more subtle.
The leading theory for why psychedelics might have lasting mental health benefits centers on neuroplasticity: the brain’s ability to form new connections between neurons. Activating serotonin receptors appears to kick off signaling cascades that promote the growth of dendritic spines, the tiny structures where neurons connect to each other. Research published in Molecular Psychiatry has shown that psychedelics can strengthen synaptic connections in cortical neurons, and that this can happen through multiple pathways, not just direct activation of the neuron receiving the signal. Whether these neuroplasticity effects occur meaningfully at microdose levels, however, remains an open question.
What the Evidence Actually Shows
This is where the story gets complicated. Surveys and open-label studies consistently show that people who microdose report improvements in mood, creativity, energy, and focus. But when researchers use the gold standard of scientific testing, double-blind placebo-controlled designs, most of those benefits evaporate.
A large “self-blinding” citizen science study coordinated by Imperial College London asked participants to set up their own placebo-controlled experiment at home. After four weeks, the microdose group showed significant improvements in psychological well-being, but so did the placebo group. There were no meaningful differences between the two. Small differences did appear on acute measures like mood and perceived creativity, but the researchers noted these could be explained by participants correctly guessing whether they had taken the real dose or the placebo.
A separate double-blind trial published in Translational Psychiatry reached a similar conclusion. Low doses of psilocybin mushrooms produced noticeable subjective effects and measurable changes in brain wave patterns, but without evidence of enhanced well-being, creativity, or cognitive function. In fact, the few statistically significant changes that did emerge leaned toward mild cognitive impairment rather than enhancement. The study’s authors concluded that expectation underlies at least some of the anecdotal benefits attributed to microdosing.
This doesn’t necessarily mean microdosing “doesn’t work.” Placebo effects are real physiological responses, and the ritual of microdosing, including setting intentions and paying closer attention to your mental state, could itself be beneficial. But based on the best available evidence, the specific pharmacological effects of psilocybin at microdose levels have not been shown to outperform a placebo.
Safety Concerns and Side Effects
Because microdoses are small, many people assume they carry minimal risk. Short-term side effects reported by microdosers tend to be mild: slight nausea, restlessness, difficulty sleeping if taken too late in the day, and occasionally increased anxiety. But the more concerning safety question involves long-term use.
Psilocin binds not only to 5-HT2A receptors but also to 5-HT2B receptors, which are found in heart tissue. Repeated activation of 5-HT2B receptors has been linked to heart valve disease with other drugs. Several medications with strong 5-HT2B binding were pulled from the market or flagged after roughly 25 percent of patients developed new valve abnormalities with prolonged use. A cardiovascular safety review published in PMC noted that psilocybin has a high potency for the 5-HT2B receptor, which suggests it could carry a relatively higher risk of valvular heart disease than some other psychedelics when used repeatedly over long periods. The authors recommended echocardiographic monitoring for anyone using psilocybin chronically in microdose form. No cases of microdosing-related heart valve disease have been documented in humans yet, but no long-term safety studies have been conducted either.
Interactions With Antidepressants
If you take an SSRI or SNRI antidepressant, psilocybin’s effects are likely to be significantly dulled. In a study of over 600 reports of people taking mushrooms while on an antidepressant, about 47 percent of those on SSRIs and 55 percent of those on SNRIs experienced weaker effects than expected. Bupropion, which works through different brain pathways, had a lower rate of dampening at around 29 percent.
Perhaps more surprising is how long this dampening lasts after stopping the medication. The probability of reduced effects remained elevated for three to six months after discontinuing an SSRI or SNRI. Removing reports involving fluoxetine (Prozac), which lingers in the body much longer than other antidepressants, didn’t change this finding. This suggests the interaction involves lasting changes in serotonin receptor sensitivity, not just the drug being present in your system. Anyone considering microdosing while on or recently off antidepressants should factor this in, and stopping psychiatric medication to try microdosing carries its own serious risks.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law, making it illegal to possess, grow, or distribute. Oregon became the first state to create a regulated framework for psilocybin-assisted therapy, and Colorado has followed with its own program for supervised use. Several cities, including Ann Arbor, Detroit, and others, have passed resolutions making enforcement of laws against psilocybin and other entheogenic plants the lowest police priority, but this is not the same as legalization.
Some states are exploring therapeutic access. A recent state budget bill earmarked funds for a pilot program offering psilocybin-assisted therapy to veterans, retired first responders, and healthcare workers at approved federal treatment sites. Internationally, psilocybin remains illegal in most countries, with Jamaica, Brazil, and the Netherlands (where psilocybin truffles are sold legally) being notable exceptions. The legal landscape is shifting, but microdosing for personal use remains illegal in the vast majority of jurisdictions.